The invention relates to a polypeptide selected from bone morphogenetic protein 10 (BMP10) or a bone morphogenetic protein 9 (BMP9) variant lacking osteogenic activity for use in the treatment of a vascular disease or a respiratory disease. The invention also relates to novel BMP9 variants and to pharmaceutical compositions comprising said polypeptides.